Cullinan Therapeutics, Inc.
CGEM
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$203M
▼ -31.4% YoY
Op. Margin
–
ROIC
-49.85%
▼ -8.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$165M
▼ -21.0% YoY
Op. Cash Flow (TTM)
-$165M
▼ -21.0% YoY
Net Debt
-$288M
Net Cash Position
Cash & Equiv.
$290M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CGEM
Held by ETFs
CGEM is in 40 US ETFs. The largest of them, with CGEM's weight in each:
Cullinan Therapeutics (CGEM) in three numbers
Questions about Cullinan Therapeutics
Is Cullinan Therapeutics a high-quality business?
Cullinan Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$288M, and its weakest is return on capital at -49.8%. The Quality tab shows every check against its target.
Does Cullinan Therapeutics (CGEM) pay a dividend?
No. Cullinan Therapeutics (CGEM) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 4 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CGEM's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CGEM
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.